Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12844283 | 0.81 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1KDM4ELMNATP53 | |
| SCHEMBL23978357 | 0.79 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1KDM4ELMNAHTT | |
| SCHEMBL15896828 | 0.78 | GAA (0.47) | SMN1; SMN2ALDH1A1KDM4ELMNAHTT | |
| SCHEMBL7993567 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1KDM4ELMNAHTT | |
| SCHEMBL5898267 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1KDM4ELMNAHTT | |
| SCHEMBL6744408 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1KDM4ELMNAHTT | |
| SCHEMBL5898273 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1KDM4ELMNATP53 | |
| SCHEMBL762264 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1KDM4ELMNAHTT | |
| Hydrochloric Acid SCHEMBL14696281 | 0.76 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1KDM4ELMNAHTT | |
| SCHEMBL805436 | 0.76 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1LMNAHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1085974-A | — | — | None | — | — | JP | disclosed |
| WO-2023220741-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | DICE MOLECULES SV, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3774775-B1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-20230158024-A1 | CD38 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2023-05-25 | — | — | US | disclosed |
| US-20220280644-A1 | \"TRPswitch\" - A STEP FUNCTION CHEMO-OPTOGENETIC LIGAND | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-09-08 | — | — | US | disclosed |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-04-21 | — | — | US | disclosed |
| US-11254670-B2 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
| EP-3589630-B1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2009050236-A1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | AMGEN INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | AMGEN INC. | 2008-06-26 | — | — | US | disclosed |
| US-7365139-B2 | Polymerisation catalyst | BP CHEMICALS LIMITED (GB) | 2008-04-29 | — | — | US | disclosed |
| WO-2008045484-A1 | N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES | AMGEN INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20070161761-A1 | Polymerisation catalyst | BP CHEMICALS LIMITED | 2007-07-12 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-7186500-B2 | Silver halide photographic lightsensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| WO-2003007959-A1 | QUINOXALINE DERIVATIVES WHICH HAVE PARP INHIBITORY ACTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | SMN1; SMN2 1844/4885ALDH1A1 2674/4885KDM4E 3386/4885 |
| US-20070161761-A1 | Polymerisation catalyst | GRM8, CHD8, CHRNA9 | SMN1; SMN2 2448/4885ALDH1A1 4218/4885KDM4E 2724/4885 |
| US-11254670-B2 | 1,8-naphthyridinone compounds and uses thereof | NME1, ADORA2A, GPR68 | SMN1; SMN2 3645/4885ALDH1A1 1543/4885KDM4E 3184/4885 |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | SMN1; SMN2 3645/4885ALDH1A1 1543/4885KDM4E 3184/4885 |
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | GLP1R, GPR119, NAT1 | SMN1; SMN2 2951/4885ALDH1A1 636/4885KDM4E 4209/4885 |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 4476/4885ALDH1A1 2100/4885KDM4E 4200/4885 |
| US-20220280644-A1 | \"TRPswitch\" - A STEP FUNCTION CHEMO-OPTOGENETIC LIGAND | TRPA1, TRPC3, TRPV1 | SMN1; SMN2 2751/4885ALDH1A1 1570/4885KDM4E 4160/4885 |
| US-20230158024-A1 | CD38 INHIBITORS | CD38, NQO1, NDUFAB1 | SMN1; SMN2 297/4885ALDH1A1 146/4885KDM4E 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.